1. Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debriso-quine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Bioph Res Co 152(1):411–6
2. Johansson I, Yue QY, Dahl ML et al (1991) Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 40(6):553–6
3. Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S (1994) Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/ sparteine) polymorphism. J Pharmacol Exp Ther 268(2):546–51
4. Mortimer O, Persson K, Ladona MG et al (1990) Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 47(1):27–35
5. Persson K, Sjostrom S, Sigurdardottir I, Molnar V, Hammarlund- Udenaes M, Rane A (1995) Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Brit J Clin Pharmacol 39(2):182–6.